Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Graypoint LLC

Graypoint LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,942 shares of the biopharmaceutical company’s stock after acquiring an additional 1,621 shares during the quarter. Graypoint LLC’s holdings in Gilead Sciences were worth $834,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Manning & Napier Advisors LLC acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at about $25,328,000. Legal & General Group Plc increased its position in Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares in the last quarter. IRON Financial LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $830,000. GSA Capital Partners LLP acquired a new stake in Gilead Sciences during the 1st quarter worth approximately $462,000. Finally, Wealth Enhancement Advisory Services LLC increased its position in Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock worth $19,630,000 after purchasing an additional 33,162 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Piper Sandler increased their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. Finally, Barclays upped their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $90.05.

Gilead Sciences Stock Performance

Shares of GILD opened at $97.90 on Friday. The business’s fifty day moving average price is $84.58 and its 200 day moving average price is $74.67. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.32. The stock has a market capitalization of $121.88 billion, a PE ratio of 119.39, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 62,437 shares of company stock valued at $5,374,825 over the last three months. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.